A framework to assess the translation of safety pharmacology data to humans

Journal of Pharmacological and Toxicological Methods

Volumn 60, Issue 2, 2009, Pages 152-158

  Valentin, Jean Pierre ^a   Bialecki, Russell ^a   Ewart, Lorna ^a   Hammond, Tim ^a   Leishmann, Derek ^b   Lindgren, Silvana ^c   Martinez, Vicente ^d   Pollard, Chris ^a   Redfern, Will ^a   Wallis, Rob ^e  

^a ASTRAZENECA   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Clinical translation; Drug discovery and development; Drug safety; Non clinical models; Predictive capacity; Predictive value; Safety pharmacology

Indexed keywords

ACCURACY; ARTICLE; CLINICAL DECISION MAKING; CONCEPTUAL FRAMEWORK; DISEASE MODEL; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PREDICTION; QT PROLONGATION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY;

ANIMALIA;

EID: 68749083601     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.05.011     Document Type: Article

References (36)

1. Ando K., Hombo T., Kanno A., Ikeda H., Imaizumi M., Shimizu N., et al. QT PRODACT: In vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 487-500
2. Anon, (2000). ICHS7A: Safety pharmacology studies for human pharmaceuticals.CPMP/ICH/539/00. London, November 16, 2000. http://www.emea.eu.int/pdfs/human/ich/053900en.pdf
3. Anon, (2005a). ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. London, 25 May 2005. CPMP/ICH/423/02. http://www.emea.eu.int/pdfs/human/ich/042302en.pdf
4. Anon, (2005b). ICH E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. London, 25 May 2005. CPMP/ICH/2/04. http://www.emea.eu.int/pdfs/human/ich/000204en.pdf
5. Anon. (2005c) Guidance document on the validation and international acceptance of new or updated test methods for hazard identification. 1-96. Organisation for Economic Cooperation and Development (OECD), Environmental Health and Safety Monograph Series on Testing and Assessment No. 34.
6. Breckenridge A. A clinical pharmacologist's view of drug toxicity. British Journal of Clinical Pharmacology 42 1 (1996) 53-58
7. Cantilena L.R., Koerner J., Temple R., and Throckmorton D.C. FDA evaluation of cardiac repolarisation data for 19 drugs and drug candidates. Clinical Pharmacology and Therapeutics 79 2 (2006) P29
8. Cavero I. Safety pharmacology society: 8th annual meeting. Expert Opin Drug Saf. 8 2 (2009) 237-247 Mar
9. De Bruin M.L., Pettersson M., Meyboom R.H.B., Hoes A.W., and Leujkens H.G.M. Anti-hERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart J. 26 (2005) 590-597
10. Fung M., Thornton A., Mybeck K., Wu J.H., Hornbuckle K., and Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceuticals markets - 1960 to 1999. Drug Information Journal 35 (2001) 293-317
11. Genschow E., Spielmann H., Scholz G., Seiler A., Brown N., Piersma A., et al. The ECVAM international validation study on in vitro embryotoxicity tests: Results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Alternatives to Laboratory Animals 30 (2002) 151-176
12. Igarashi T., Nakane S., and Kitagawa T. Predictability of clinical adverse reactions of drugs by general pharmacologystudies. J Toxicol Sci 20 (1995) 77-92
13. Kennedy T. Managing the drug discovery / development interface. Drug Disc. Dev. 2 (1997) 436-444
14. Joel D. Current animal models of obsessive compulsive disorder: A critical review. Progress in Neuro-Psychopharmacology & Biochemical Psychiatry 30 (2006) 374-388
15. Keating, C., Martinez, V., Valentin, J. P., Grundy, D. (2009). An in vitro motility assay as a predictive model of gastrointestinal adverse drug reactions. The Toxicologist (in press).
16. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews / Drug Discovery 3 (2004) 711-715
17. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. J.A.M.A. 287, 2215-2220.
18. Lawrence C.L., Bridgland-Taylor M.H., et al. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol 149 (2006) 845-860
19. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Journal of the American Medical Association 279 15 (1998) 1200-1205
20. McKinney Jr. W.T. Models of mental disorders: A new comparative psychiatry (1988), Plenum Medical Book Co., New York
21. Miyazaki H., Watanabe H., Kitayama T., Nishida M., Nishi Y., Sekiya K., et al. QT PRODACT: Sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 523-529
22. Omata T., Kasai C., Hashimoto M., Hombo T., and Yamamoto K. QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Journal of Pharmacological Sciences 99 (2005) 531-541
23. Pugsley M.K., Authier S., and Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 154 (2008) 1382-1399
24. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
25. Redfern W.S., Wakefield I.D., Prior H., Hammond T.G., and Valentin J.P. Safety pharmacology - A progressive approach. Fundamental and Clinical Pharmacology 16 (2002) 161-173
26. Redfern W.S., and Wakefield I.D. Safety pharmacology. In: Keller K., and Jacobson-Kram D. (Eds). Toxicological testing handbook: Principles, applications and data interpretation. 2 (2006), Taylor & Francis Ltd
27. Redfern W.S., Waldron G., Winter M.J., Butler P., Holbrook M., Wallis R., and Valentin J.-P. Zebrafish assays as early safety pharmacology screens: Paradigm shift or red herring?. J Pharmacol Toxicol Methods 58 (2008) 110-117
28. Richards F.M., Aderton W.K., Kimber G.M., Lui Z., Strang I., Redfern W.S., Valentin J.-P., Winter M.J., and Hutchinson T.H. Validation of the use of zebrafish larvae in visual safety assessment. J Pharmacol Toxicol Methods 58 (2008) 50-58
29. Sasaki H., Shimizu N., Suganami H., and Yamamoto K. QT PRODACT: Inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. Journal of Pharmacological Sciences 99 (2005) 513-522
30. Stephens, M.D.B. (2004). In: J Talbot & P Waller (Eds.), "Stephens' detection of new adverse drug reactions", fifth edition (pp. 1-91).
31. Valentin, J.P., Hammond, T.G. (2006). Safety Pharmacology: Past, Present and Future. Book Chapter in "The Process of New Drug Discovery and Development" Eds Smith C.G. Ed J. O'Donnell, pp 243-290.
32. Valentin J.P., and Hammond T.G. Safety and secondary pharmacology: Successes, threats, challenges and opportunities. Journal of Pharmacological and Toxicological Methods 58 (2008) 77-87
33. Wallis, R. (in press) Integrated risk assessment and predictive value to humans of non-clinical repolarisation assays. Br. J. Pharmacol.
34. Webster R., Leischmann D., and Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Current Opinion in Drug Discovery and Development 5 (2002) 116-126
35. Wilner P. The validity of animal models of depression. Psycopharmacology 83 1 (1984) 1-16
36. Winter M.J., Redfern W.S., Hayfield A.J., Owen S.F., Valentin J.-P., and Hutchinson T.H. Validation of a larval zebrafish locomotor assay for assessing the seizure-liability of early-stage development drugs. J Pharmacol Toxicol Methods 57 (2008) 176-187